Aspirin for Colorectal Cancer Camp Lejeune NC

Taking aspirin might not only reduce the risk of getting colorectal cancer, but it also might lower the odds of dying if you have it, new research suggests. People with colorectal cancer#日# who took aspirin regularly had a 29 percent lower risk for death from the cancer and a 21 percent lower risk for death from other causes, according to the research, reported in the Aug. 12 issue of the Journal of the American Medical Association.

James M Coghill, MD
(919) 966-4970
CB 7305 3009 Old Clinic Bldg,
Chapel Hill, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Nishan Hesiri Fernando, MD
(919) 681-5257
Box 3477 Duke Univ Medical Ctr,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1997

Data Provided by:
Michael Stanley Serwint, MD
(704) 872-3630
542 Brookdale Dr
Statesville, NC
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Univ Of Chicago, Pritzker Sch Of Med, Chicago Il 60637
Graduation Year: 1975

Data Provided by:
Murat O Arcasoy, MD
(919) 668-6309
DUMC Box 3912,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Michael John Kelley, MD
919-286-0411 x 7326
508 Fulton St # 111G
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1985

Data Provided by:
Marc Lester Slatkoff, MD
(336) 768-0325
7905 Fair Oaks Ct
Clemmons, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Fl Coll Of Med, Gainesville Fl 32610
Graduation Year: 1974

Data Provided by:
Virgil Lowell Rose Jr, MD
(919) 431-9201
3320 Wake Forest Rd Ste 120
Raleigh, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ok Coll Of Med, Oklahoma City Ok 73190
Graduation Year: 1980

Data Provided by:
Jennifer Lynn Garst, MD
(919) 684-5808
Box 3198 Rm 25178 Morris Bldg,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Med Coll Of Ga Sch Of Med, Augusta Ga 30912
Graduation Year: 1990

Data Provided by:
Sascha A Tuchman
(919) 684-8111
2100 Erwin Rd
Durham, NC
Specialty
Hematology

Data Provided by:
Frank M Torti
(336) 716-2255
Medical Center Blvd
Winston Salem, NC
Specialty
Medical Oncology

Data Provided by:
Data Provided by:

Aspirin for Colorectal Cancer

Provided By:

Taking aspirin might not only reduce the risk of getting colorectal cancer, but it also might lower the odds of dying if you have it, new research suggests.

People with colorectal cancer who took aspirin regularly had a 29 percent lower risk for death from the cancer and a 21 percent lower risk for death from other causes, according to the research, reported in the Aug. 12 issue of the Journal of the American Medical Association.

After an average of about 12 years, 35 percent of the 549 people with colorectal cancer who took aspirin had died. That included about 15 percent whose death was attributed to the cancer.

Among 730 people with colorectal cancer who did not take aspirin, 39 percent had died, including 19 percent from the cancer.

The overall five-year survival rate was 88 percent for people who used aspirin, compared with 83 percent for those who did not. The 10-year survival rate was 74 percent for aspirin users and 69 percent for those who didn't use aspirin.

Researchers used data on 1,279 men and women with stage 1, 2 or 3 nonmetastatic colorectal cancer who were participating in two large studies, the Nurses Health Study that began in 1980 and the Health Professionals Follow-up Study that began in 1986.

"It's a pretty significant benefit and does suggest aspirin may have a role in treatment of patients with established colorectal cancer as well as for the prevention of developing initial tumors," said the study's lead author, Dr. Andrew Chan, a gastroenterologist at Massachusetts General Hospital and an assistant professor of medicine at Harvard Medical School.

Among 719 participants who had not used use aspirin before their cancer diagnosis, starting to take it once they'd been diagnosed was associated with a 47 percent lower risk for dying from the cancer and a 32 percent lower risk for dying prematurely from any cause.

The benefits linked to aspirin were especially evident among people with COX-2 positive tumors.

Previous research has shown that aspirin might reduce the chances of developing colorectal cancer tumors by inhibiting cyclooxygenase (COX-2) enzyme, Chan said. COX-2, which contributes to inflammation and cell proliferation, is overproduced in about 65 to 80 percent of human colorectal cancers, he said.

Researchers were able to test for the COX-2 overproduction in 459 people. Among those with what are known as "COX-2 positive" tumors, regular aspirin use after diagnosis was associated with a 61 percent lower risk for dying from colorectal cancer and 38 percent lower risk for premature death from any cause.

However, those who had "COX-2 negative" tumors and who took aspirin did not show decreased mortality, according to the study.

Nor did the researchers find much benefit for people who had been using aspirin before their cancer diagnosis. For them, continuing to take aspirin during and after their cancer treatment was not associated with a significant reduction in colorectal survival, Chan said.

"What that suggests is that those who developed cancer despite being on aspirin were probably developing cancers that were relatively resistant to aspirin," he said. "There are some tumors that are responsive to the effects of aspirin and some that are not."

Despite mounting evidence of aspirin's potential cancer-fighting properties, Chan stopped short of recommending that it be used to prevent or treat colorectal cancer.

Aspirin can cause side effects, including gastrointestinal bleeding. Further studies, including placebo-controlled trials of aspirin and other anti-inflammatory agents, are needed, he said.

"What we need before we make definitive clinical recommendations for all patients with colorectal cancer are large-scale, randomized, controlled trials to demonstrate benefits," Chan said. "That's the gold standard."

Dr. Alfred Neugut, a professor of medicine and epidemiology at Columbia University, who wrote an accompanying editorial, called the results "provocative."

"What makes this study more convincing than the average study was they measured COX-2 and were able to show that the aspirin helped those who were 'COX-2 positive' but had no significant effect on 'COX-2 negative' patients," Neugut said. "That's what's so elegant."

Neugut agreed that it was too soon to recommend aspirin as a means of preventing colorectal cancer. But an ongoing clinical trial sponsored by the National Cancer Center of Singapore might provide the necessary evidence, he added.

"Even though the study is very, very strong, most doctors would say we need a randomized trial," Neugut said. "If you're taking aspirin for cardiovascular disease prevention, you are probably getting a bonus in terms of it preventing colon cancer, but I wouldn't recommend it solely for colon cancer prevention."

More information

The American Cancer Society has more on colorectal cancer.

SOURCES: Andrew Chan, M.D., M.P.H., assistant professor, medicine, Harvard Medical School, and gastroenterologist, Massachusetts General Hospital, Boston; Alfred I. Neugut, M.D., Ph.D., professor, medicine and epidemiology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York City; Aug. 12, 2009, Journal of the American Medical Association

Author: By Jennifer Thomas
HealthDay Reporter

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com